Skip to main content
Journal cover image

Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.

Publication ,  Journal Article
Douglas, SR; Thomas, SM; van den Bruele, AB; Wang, T; Parrish, KM; Rosenberger, LH; Plichta, JK; DiNome, ML; Chiba, A
Published in: Ann Surg Oncol
January 2026

BACKGROUND: The COVID-19 pandemic restricted operating room availability, prompting the Pandemic Breast Cancer Consortium to issue guidelines on deferring non-urgent surgical procedures. This led to an increased use of neoadjuvant endocrine therapy (NET) for estrogen-receptor positive (ER+) breast cancers. Irrespective of the pandemic, the ACOSOG Z1031 trial demonstrated that NET was effective at downstaging 51% of patients initially ineligible for breast conserving surgery (BCS). Despite this, NET utilization remains low. This study investigates NET use and related outcomes before, during, and after the pandemic. METHODS: Patients aged ≥ 18 with clinical T1-T4c, N0-3, ER+/HER2- breast cancers were selected from the National Cancer Database and stratified into two groups: NET versus surgery first. The study analyzed trends from 2019 (pre-pandemic) to 2021 (tail-end-pandemic). Logistic regression identified factors associated with NET utilization. RESULTS: Results showed that 10,935 (3.9%) patients received NET and 272,546 (96.1%) underwent surgery first. NET use peaked in 2020 at 6.4% (vs. 2019 2.3% and 2021 3.2%, P = 0.001). Median time from diagnosis to treatment was significantly shorter in the NET group (1.02 vs. 1.35 months, P = 0.001). Patients with clinical T3-4 disease who received NET versus surgery first had similar rates of BCS and were less likely to receive chemotherapy. CONCLUSION: The use of NET nearly tripled during the COVID-19 pandemic and was associated with decreased time to treatment and less use of adjuvant chemotherapy. NET could be considered for patients requiring a delay to surgery or for those with higher T-category who desire BCS or are unable to tolerate chemotherapy.

Duke Scholars

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

January 2026

Volume

33

Issue

1

Start / End Page

86 / 94

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Practice Patterns, Physicians'
  • Pandemics
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Douglas, S. R., Thomas, S. M., van den Bruele, A. B., Wang, T., Parrish, K. M., Rosenberger, L. H., … Chiba, A. (2026). Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic. Ann Surg Oncol, 33(1), 86–94. https://doi.org/10.1245/s10434-025-18307-4
Douglas, Sasha R., Samantha M. Thomas, Astrid Botty van den Bruele, Ton Wang, Kendra M. Parrish, Laura H. Rosenberger, Jennifer K. Plichta, Maggie L. DiNome, and Akiko Chiba. “Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.Ann Surg Oncol 33, no. 1 (January 2026): 86–94. https://doi.org/10.1245/s10434-025-18307-4.
Douglas SR, Thomas SM, van den Bruele AB, Wang T, Parrish KM, Rosenberger LH, et al. Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic. Ann Surg Oncol. 2026 Jan;33(1):86–94.
Douglas, Sasha R., et al. “Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic.Ann Surg Oncol, vol. 33, no. 1, Jan. 2026, pp. 86–94. Pubmed, doi:10.1245/s10434-025-18307-4.
Douglas SR, Thomas SM, van den Bruele AB, Wang T, Parrish KM, Rosenberger LH, Plichta JK, DiNome ML, Chiba A. Neoadjuvant Endocrine Therapy Use in Estrogen Receptor Positive Breast Cancer: Insights from Practice Shifts During the COVID-19 Pandemic. Ann Surg Oncol. 2026 Jan;33(1):86–94.
Journal cover image

Published In

Ann Surg Oncol

DOI

EISSN

1534-4681

Publication Date

January 2026

Volume

33

Issue

1

Start / End Page

86 / 94

Location

United States

Related Subject Headings

  • SARS-CoV-2
  • Receptors, Estrogen
  • Receptor, erbB-2
  • Receptor, ErbB-2
  • Prognosis
  • Practice Patterns, Physicians'
  • Pandemics
  • Oncology & Carcinogenesis
  • Neoadjuvant Therapy
  • Middle Aged